Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions after trastuzumab and/or lapatinib based therapy
Breast Neoplasms|Neoplasm Metastasis
DRUG: Vinorelbine|DRUG: Investigator's choice of treatment|DRUG: afatinib|DRUG: afatinib
Patient Benefit Rate at 12 Weeks, Percentage of patients with patient benefit at week 12. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS), no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1, 12 weeks from randomisation
Progression-Free Survival, Progression-Free Survival is defined as the time from the date of randomisation to the date of disease progression or death whichever came first.

Disease progression was defined as either disease progression in CNS lesions (including worsening in NSS and use of corticosteroid) or disease progression in extra-CNS lesions according to RECIST 1.1., From first drug administration until 28 days after end of treatment, up to 805 days|Overall Survival, Overall Survival is defined as time from randomisation to the date of death from any cause., From first drug administration until 28 days after end of treatment, up to 805 days
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions after trastuzumab and/or lapatinib based therapy